HaRo Pharmaceuticals, Inc. is a biotechnology and pharmaceutical company developing hybrid molecules for the treatment of cancer. HaRo's proprietary products, in early stage development, modulate cell differentiation and proliferation in neural crest-derived tumors, leukemia, and other poorly differentiated cancers. HaRo's compounds target just the cancer cells, leaving the surrounding tissue intact and undamaged.
